uniQure Faces Investigation as Huntington's Disease Drug Data Disappoints
uniQure N.V.'s stock price dropped significantly after its AMT-130 Huntington's disease drug showed less benefit at 48 months than previously reported at three years.
Shares of uniQure N.V. (NASDAQ: QURE) fell sharply by 39% on September 29, 2026, following the release of disappointing 48-month data for its AMT-130 drug candidate for Huntington's disease. The company's prior report at 36 months had indicated a greater treatment benefit.
Law firm SueWallSt has announced a pending investigation into potential securities law violations related to uniQure's statements. Investors who have incurred losses on QURE stock are being advised to submit their information for a review of their potential claims.
According to the released data, AMT-130 demonstrated only a 44% slowing of disease progression at 48 months, as measured by the Uniform Huntington's Disease Rating Scale. This is a notable decrease from the 75% slowdown previously reported by the company at the 36-month mark.
The company had submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) on September 2, based on the earlier three-year data. The investigation will examine whether uniQure made materially false or misleading statements about its clinical results and their durability prior to the release of the 48-month findings.
Investors who purchased QURE stock and experienced losses are eligible to participate in the investigation, regardless of whether they still hold the shares. SueWallSt, associated with Levi & Korsinsky LLP, is conducting the review.